CurifyLabs
An automated 3D printing platform designed for personalized medicine, enabling pharmacies and hospitals to manufacture tailored drug dosages on-site.
- CEO / Founder
- Charlotta Topelius
- Team Size
- 11-50
- Stage
- Commercial growth stage; recently secured €6.7M Series A funding (May 2025) with systems already deployed in clinical and pharmacy settings.
- Total Funding
- €17.6M
- Latest Round
- Funding round
- Key Investors
- ["Lifeline Ventures","Springvest","Pharmacy Pension Fund (Apteekkien Eläkekassa)","Business Finland","European Innovation Council (EIC)"]
Technology & Products
Key Products
["Curify Mini (Pharmaceutical-grade 3D Printer)","Pharma Inks (Proprietary drug-loaded formulations)","Curify Software Suite (Cloud-based platform for dosage design and quality control)","Validation & Quality Control Kits (Ensuring medical-grade compliance)"]
Technological Advantage
Utilizes a proprietary 'Tailored Dose' technology that combines hardware, software, and validated ink formulations, allowing for the production of complex drug combinations and specific release profiles that are impossible with traditional tableting.
Market & Competition
Target Customers
Compounding pharmacies, hospital pharmacies, veterinary clinics, and pharmaceutical research institutions.
Industry Verticals
["Healthcare","Pharmaceuticals","Veterinary Medicine","Personalized Medicine"]
Competitors
["Aprecia Pharmaceuticals","FabRx","CraftHealth"]